News for BioMarin Pharmaceutical Inc. (0HNC.L)

On July 22, 2025, Morgan Stanley released an update on BioMarin Pharmaceutical (BMRN) involving a revised price target. Analyst Matthew Harrison maintained the

On July 14, 2025, JP Morgan analyst Jessica Fye announced an update on BioMarin Pharmaceutical (BMRN) by maintaining an "Overweight" rating for the company. Thi

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 11 best debt-free stocks to invest in right now. On July 2, Morgan Stanley analyst Sean Laaman initiated coverage on BioMarin with a Buy rating and a $97 price target, citing a favorable outlook despite ongoing competitive concerns. Laaman’s optimism centers on Voxzogo, BioMarin’s therapy for achondroplasia, a […]

The ClearBridge Sustainability Leaders Strategy outperformed its Russell 3000 Index benchmark in the second quarter. Read more here.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On July 1, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced the finalization of its acquisition of Inozyme Pharma, Inc. The deal is valued at $270 million, and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has paid $4.00 per share in cash for all […]

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) at a Buy rating with a price target of $86.00 in a report published on June 10. According to BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s most recent earnings report, the firm […]

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)  is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of Barclays kept BioMarin Pharmaceutical Inc.

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. ( INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the ”œA

BioMarin Pharmaceutical Inc. (BMEA) has announced a new stock offering, which has been priced lower than its previous closing price of $2.90. Jefferies is takin

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 16 stocks Jim Cramer recently discussed. When a caller asked about the company during the lightning round, Cramer remarked: “You know what, BioMarin, I am getting tired of the orphan drug model. I just… [don’t] think that it’s working. I think it worked for some time. I […]

Jim Cramer recommends Union Pacific but is

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

PR NewswireNEW YORK, May 22, 2025 NEW YORK, May 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following comp

On May 20, 2025, Erin Burkhart, Chief Accounting Officer at GVP, executed a sale of 1,786 shares of Biomarin Pharmaceutical Inc (BMRN). Following this transacti

PR NewswireNEW YORK, May 19, 2025 NEW YORK , May 19, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following com

NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of

On May 16, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced a $270 million acquisition of Inozyme Pharma, aiming to expand its rare disease research. The all-cash deal, backed by both companies’ boards, is expected to close between July and September, giving BioMarin control of INZ-701, an enzyme replacement therapy targeting ENPP1 and ABCC6 deficiencies, life-threatening disorders caused by […]

BioMarin (BMRN) is set to enhance its enzyme therapy offerings through the acquisition of a promising late-stage treatment, INZ-701. This enzyme replacement the

PR NewswireSAN RAFAEL, Calif. and BOSTON, May 16, 2025 Acquisition is Strong Strategic Fit for BioMarin, Adding INZ-701, a Phase 3 Enzyme Replacement Thera